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An aberrant operation of the autocrine self-stimulation has been postulated to
be one ofthe mechanisms leading cells to malignant transformation (1-3). Cells could
escape from normal growth control and become malignant by endogenous produc-
tion of growth factors acting on themselves via functional external receptors . The
autocrine action in cancer cellsof growth factors such as transforming growth factor
and platelet-derived growth factor has been demonstrated in certain virus-transformed
cells (4-7). A number of experiments have been recently reported that show the rela-
tionship of endogenous production of a growth factor(s) to malignant transforma-
tion in fibroblasts and hematopoietic cells by means of transfection and expression
of genes coding for: granulocyte-macrophage colony stimulating factor (GM-CSF),'
transforming growth factor a, epidermal growth factor, and fibroblast growth factor
(8-12).
IL-2 autocrine stimulation has been demonstrated for the in vitro growth of a
human T cell line isolated from a patient with non-Hodgkin T cell lymphoma (13),
and not conclusively but suggestively, a gibbon T cell line MLA144 isolated from
a spontaneous lymphosarcoma (14). Furthermore, evidence has been accumulated
to suggest the involvement of the aberrant activation of the IL-2 autocrine loop in
the development of adult T cell leukemia (ATL) by the infection of CD4+ helper
T cells with human T cell leukemia virus type 1 (HTLU1) (15-22). Recent work
has shown that the infection of an IL-2-dependent murine cytotoxic T cell line (CTLL-
2) with a retrovirus vector carrying the human IL-2 gene resulted in factor-independent
growth in vitro and tumorigenicity in vivo (23). However, the growth autonomy
of the CTLL-2 transfectants does not seem to be governed by the IL-2 autocrine
mechanism as discussed later.
The generation of cells that constitutively both express IL-2-R and secrete IL-2
should provide a model system to assess the autocrine hypothesis in the malignant
transformation of T cells. In the present study, we introduced an expression vector
carrying a mouse IL-2 cDNA into an IL-2-dependent murine T cell line HT2, which
was derived from T cells that provide I-Ad-restricted help to B cells for anti-sheep
red blood cell response (24). The transfectants proliferated in vitro autonomously
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through an IL-2 autocrine mechanism and the higher producers of IL-2 developed
tumors in vivo. Our results indicate that the dysregulation of an IL-2 system is in-
volved in an autocrine fashion in the development of T cell malignancies in vivo.
Materials and Methods
Plasmid Construction.
￿
Enzymatic manipulations of DNA and preparation ofplasmid DNA
were performed according to standard procedure (25). A cDNA expression vector BCMGNeo
was constructed from the vector BMGNeo (26) and the plasmid pRR23 (27) kindly provided
to us by Dr. B. Fleckenstein, Institut für Klinische Virologie der Universtitdt Erlangen-Niirn-
berg, Erlangen, FRG. The 710-bp long Xba I-Sal I fragment containing mouse metallothio-
nein-I promoter in BMGNeo was replaced in BCMGNeo with the 745-bp long Hind III-
Sac II fragment of pRR23 carrying the human CMV promoter and enhancer after the sites
of Hind III and Sac II had been converted to Xba I and Sal I sites, respectively, by ligation
of synthetic linkers. BCMGNeo mIL-2 was constructed by first ligating Xho I linkers to the
563-bp long Pst I-Ssp I fragment of mouse IL-2 cDNA (a generous gift of Dr. W. Fiers,
State University ofGhent, Belgium) and subsequent ligation of the fragment into the Xho I
site of BCMGNeo.
Northern Blot Analysis.
￿
Preparation of total RNA, denaturation with glyoxal, electropho-
resis in 1.4% agalose gel, and transfer onto nylon membrane were performed as described
previously (25). The 563-bp long Pst I-Ssp I fragment of mIL-2 cDNA and the 560-bp long
Xho I-Bam HI fragment containing rabbit ß-globin DNA of the vector BCMGNeo were
subcloned into the plasmid pSK(+) (Stratagene, La Jolla, CA). '32P-labeled RNA probes
complementary to mRNA were prepared from the linearized plasmids by using T3 RNA
polymerase. Northern filters were hybridized overnight with .,2P-labeled RNA probes in 50%
formamide/5 x SSC/50 mM Tris (pH 7 .5)/5 mM EDTA/0.1°Io sodium pyrophosphate/1%
SDS/0.2 % polyvinylpyrolidone/0.2% ficoll/0.2 % BSA/150 wg/ml denatured salmon sperm
DNA at 68°C. The filters were washed at 68°C twice in 1 x SSC/0.1°Io SDS for 15 min each,
twice in 0.3 x SSC/0.1% SDS for 15 min each, and then twice in 0.1 x SSC/0.1% SDS for
15 min each before autoradiography.
Cell LinesandCulture.
￿
An IL-2-dependent helper T cell line HT-2 derived from a BALB/c
mouse (24) and the plasmid-transfected HT-2 cells were maintained in RPMI 1640 medium
supplemented with 10% FCS (Gibco Laboratories, Grand Island, NY), 100 U/ml ofpenicillin-
streptomycin (Gibco Laboratories), 2 MM L-glutamine (Gibco Laboratories) and 5 x 10-5 M
2-ME.
DNA Transfection.
￿
DNA transfection was performed by the protoplast fusion technique.
Bacteria bearing the appropriate plasmids were converted to protoplasts and fused to HT-2
cells by using polyethylene glycol 2,000 (Wako Pure Chemical Industries, Osaka, Japan) as
described previously (28). 2 d after fusion cells were cultured in the presence of 1 mg/ml
of G418 (Gibco Laboratories, Paisley, Scotland) and 50 U of murine (m) rIL-2 (26). Among
G418-resistant transfectants, those grown in the absence of exogenous IL-2 were selected,
and then subcloned by the limiting dilution method in the presence of mrIL-2. Subclones
of transfectants were thereafter maintained in media without G418 and exogenous IL-2.
AssayforIL-2 Activity.
￿
IL-2 activity was measured by the [3H]thymidine uptake of IL-2-
dependent mouse cytotoxic T cell line CTLL-2 (29). Serial dilutions of IL-2 were incubated
with 5,000 CTLL-2 cells in a volume of 200 ul for 24 h, followed by a 6-h pulse of 1 gCi
of [3H]thymidine (Amersham, Tokyo, Japan). 1 U of activity was defined as the amount of
IL-2 that induced 50% of maximal proliferation in a 200-u1 culture.
Cell Proliferation Assay.
￿
Cells were cultured at 5 x 103 cells/0.2 ml (Fig. 2 and Table II)
or at indicated densities shown in Fig. 3 in the presence or absence of mrIL-2 for 24 h (Fig.
2 and Table II) or for 48 h (Fig. 3), followed by a 6-h pulse of 1 PCi of ['H]thymidine, and
[3H]thymidine incorporation was measured. In the growth inhibition assay, rat anti-mouse
IL-2-R antibodies AMT-13 (30), 7D4, and 3C7 (31); mouse anti-human IL-2 antibody DMS-1
crossreactive with mouse IL-2 molecules (32); or rat anti-mouse IL-4 antibody 11Bll (33)
were added at the beginning of the cultures.
Transplantation of HT2 Transfectants.
￿
HT-2 transfectants (106 or 102 cells) were injected sub-KARASUYAMA ET' AL.
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cutaneously into BALB/c mice (6-8 wk old; Shizuoka Agricultural Cooperative Association
for Laboratory Animals, Hamamatsu, Japan) or BALB/c nu/nu mice (6-7 wk old; CLEA
Japan Inc., Tokyo, Japan). Mice were monitored twice a week for the appearanceofsolid tumor.
Results
Transfection ofan IL-2-dependent Mouse Helper T Cell Line with Mouse IL-2 cDNA.
￿
An
mIL-2 cDNA (cloned by W. Fiers, unpublished data), from which most of the 3'
untranslated region containing A and T nucleotide-rich sequences responsible for
the destabilization of transcripts has been deleted, was inserted into the expression
vector BCMGNeo derived from the vector BMGNeo (26) to construct the plasmid
BCMGNeo - mIL-2. In this construct, the transcription of mIL-2 cDNA is under
the control of the promoter/enhancer of human CMV (27), which has been found
to be 10 times stronger than the mouse metallothionein I promoter on BMGNeo
vector (our unpublished observation). A helper T cell line HT-2 derived from a BALB/c
mouse (24), which is absolutely dependent on exogenously supplied IL-2 for its sur-
vival and proliferation, was transfected with BCMGNeo - mIL-2 by means of the
protoplast fusion technique (34). G418-resistant stable transfectants were obtained
in the presence of exogenous IL-2 at the frequency of 10' . Among these transfec-
tants ti5% of clones could grow in the absence ofadded IL-2, while any ofthe HT-2
cells transfected with the vector BCMGNeo alone could not. The G418-resistant
transfectants grown in the absence of exogenous IL-2 were subcloned and four inde-
pendent clones, K9-18, K21-1, K26-16, and K28-6, were established for further analysis.
Autonomous Growth of mIL-2 cDNA-transfected HT.2 Clones through the IL-2 Autocrine
Loop. To determine whether the autonomous growth of mIL-2 cDNA-transfected
HT-2 clones is mediated by an IL-2 autocrine mechanism, we first examined the
presence of IL-2 activity in the culture media from the HT -2 transfectants by
['H]thymidine incorporation of an IL-2-dependent cytotoxic T cell line CTLL-2
(29) (Table I). The IL-2 cDNA transfectants synthesized and secreted IL-2 ranging
from 20 to 400 U/10' cells in 48-h culture, whereas no detectable IL-2 was found
TABLE I
Secretion of IL-2 by IL-2 cDNA-transfected HT-2 Cells
' Media conditioned for 48 h by cells (106/ml) were tested for IL-2 activity on
CTLL-2 cells by [3H]thymidine uptake (see Materials and Methods).
1 Cells of a bulk culture derived from one of tumors developed in nude mice
inoculated with the IL-2 cDNA transfectant K21-1 .
5 For comparison, thymic lymphoma EL-4 cells (106/ml) were stimulated for
48 h with 5 ng/ml of PMA to secrete IL-2 .
Cell line Plasmid IL-2 secretion'
U/ml
HT-2 - <0.1
H6 BCMGNeo <0.1
H15 BCMGNeo <0.1
K9-18 BCMGNeo.mlL-2 287
K21-1 BCMGNeo mIL-2 427
K26-16 BCMGNeo-mIL-2 76
K28-6 BCMGNeo-mlL-2 24
T61 BCMGNeo mIL-2 232
EL-45 - 1,6891 6
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in media conditioned by HT-2 cells untransfected or transfected with the vector alone.
Northern blot analysis revealed that IL-2-specific transcripts in the transfectants carried
the sequence derived from rabbit ß-globin gene of the expression vector BCMGNeo
(Fig . 1) . Therefore, the IL-2 production ofthe transfectants was caused by the trans-
fected DNA and not by the activation of an endogenous IL-2 gene .
We next examined the responsiveness to IL-2 of these IL-2-secreting HT-2 trans-
fectants by the proliferaiton assay. As shown in Fig . 2 A, the transfectant K21-1 in-
corporated [3Hlthymidine in the absence of exogenous IL-2 . The addition ofmIL-
2 (26) as well as its own conditioned media increased [ 3Hlthymidine uptake in a
dose-dependent manner, indicating that the transfectant responded to IL-2 secreted
by itself. K21-1 also responded to rIL-4 (26), as do untransfected HT2 cells . A similar
responsiveness to IL-2 and IL-4was observed in the other three clones as well (data
not shown) . The influence of cell density on the proliferation of the transfectants
was further examined, because we noticed that their growth was greatly slowed and
the cell viability became lower when they were maintained at too low densities . The
transfectant K21-1 maintained at relatively high density (2-5 x 105/ml) was replated
at various cell densities ranging from 1 x 103 to 3 .2 x 104 cells/ml) in the presence
or absence of exogenous IL-2, and their proliferation was determined by [3Hlthymi-
dine incorporation (Fig . 3) . The proliferation rate expressed as [3Hlthymidine in-
corporation per cell declined as cell density became lower in the absence of exoge-
nous IL-2 (Fig . 3 B) . However, the addition of IL-2 rendered the rate constant
regardless of cell density, as observed in untransfected HT-2 cells (Fig . 3 A) . This
result indicated that the autonomous growth of the transfectants required accumu-
lation of autogenous IL-2 in the surrounding media . Indeed the K21-1 clone at low
FIGURE 1 .
￿
Northern blot analysis ofIL-2-specific
transcripts in IL-2 cDNA-transferred HT-2 cells .
Total cellular RNA (20 ug) from the following
cell lines was electrophoresed on 1 .4% agarose
gel, transferred to nylon membrane, and succes-
sively hybridized with (A) a 32P-labeled mIL-2
cDNA probe and with (B) a 3zP-labeled rabbit
ß-globin gene probe derived from the vector
BCMGNeo. (Lane 1) Thymic lymphoma EL-4
cells as a control, (lane 2) EL-4 cells stimulated
with PMA, (lane 3) untransfected HT-2 cells,
(lane 4) HT-2 transfectant K21-1, (lane 5) HT-2
transfectant K9-18.r
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FIGURE 2 .
￿
Proliferative respon-
siveness to IL-2 of IL-2 cDNA-
transfected HT-2 cells and tu-
mor-derived cells . (A) IL-2
cDNA transfectant K21-1 (5 x
103 cells/0.2 ml) was cultured
for 24 h in the absence (/) or
in the presence of serially di-
luted murine HL-2 (O), murine
rIL-4 (A), or mediaconditioned
for 48 h by K21-1 cells (41),
followed by a 6-h pulse of
[3H]thymidine . The titers of
2
￿
rIL-2and rIL-4 before dilution
were 640and 40 U/ml, respec-
tively. (B) Cells ofa bulk culture
0
￿
(T6) derived from a tumor in a
14 12 10 8 6 4 2
￿
nude mouse inoculated with
Lo92 Dilution
￿
K21-1 cells were cultured in the
absence(/) or presence (O) of
murine rIL-2 .
8-
4-
cell density without exogenous IL-2 could not form any colonies in soft agar (our
unpublished observation) .
Since all the growth properties of the HT-2 transfectants shown above suggested
that their autonomous growth was operated through an IL-2 autocrine mechanism,
we further examined whether reagents that block the IL-2/IL-2-R autocrine loop
would affect the growth ofthe transfectants (Table II) . The proliferation of the K21-1
clone was almost completely inhibited by mAbs against the IL-2-R : AMT-13 (30),
71314, and3C7 (31), which did not affect the proliferation ofcontrol HT-2 cells stimu-
FIGURE 3 .
￿
The rate of cell proliferation as a function of cell density in IL-2 cDNA-transfected
HT-2 cells and tumor-derived cells . (A) Untransfected HT-2 cells, (B) IL-2 cDNA transfectant
K21-1, (C) cells of a bulk culture (T6) derived from a tumor in a nude mouse inoculated with
K21-1 cells . Cells plated at different cell densities were cultured for 48 h in the absence (O) or
presence of 100 U/ml HL-2 ("), followed by a 6-h pulse of [3H]thymidine . The proliferation
rate expressed as [3H]thymidine incorporation (cpm) per cell at different densities is plotted on
a logarithmic-logarithmic scale .1 8
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TABLE II
Inhibition of Cell Proliferation by mAbs to IL-2 and IL-2-R
(3H]thymidine uptake'
Cells (5 x 103/0.2 ml) were cultured for 24 h with or without addition of mAbs
at indicated dilutions, followed by a 6-h pulse of [3H]thymidine.
1 HT-2 cells were incubated with 1 .4 U of rIL-4, which induced 65% of max-
imal response in this condition.
f Ascitic form.
~~ Percent inhibition is shown in parentheses.
Culture supernatant of the hybridoma.
lated with IL-4. The anti-IL-2 mAb DMS-1 (32) also inhibited the proliferation
of K21-1 to the same extent, whereas the anti-IL-4 mAb 111311 (33), which com-
pletely blocked the proliferation of HT-2 cells stimulated with IL-4, had no effect
on that of K21-1 . These results confirmed that both IL-2 molecules secreted by the
transfectants and IL-2-R expressed on their surface contributed to their autono-
mous growth.
Tumortgenicity of IL-2 cDNA-transfected HT2 Clones.
￿
To assess the hypothesis that
cells could become tumorigenic by autocrine growth stimulation, we tested the IL-2
cDNA-transfected HT2 clones for their ability to cause tumors in mice. As shown
in Table III, no tumors developed during an observation period of at least 20 wk
in syngeneic BALB/c mice injected subcutaneously with 10' or 10' cells of the IL-2
cDNA transfectants. This was also the case in 300 rad irradiated mice. Neither in-
travenous nor intraperitoneal injection of cells caused tumors or leukemias in BALB/c
mice. In contrast, when injected into BALB/c nude mice, three of four transfectants
tested produced progressively growing tumors, while HT-2 cells untransfected or
transfected with the vector alone did not (Table III: HT-2, H6, H15). Two clones,
K9-18 and K21-1, which secreted 287 and 427 U/ml ofIL-2, respectively, were tumor-
genic when 106 or 10' cells were inoculated. Two of five nude mice injected with
107 cells of K26-16, the IL-2 production of which was 76 U/ml, developed tumors,
while the inoculation of 10' cells did not produce any tumors . On the other hand,
K28-6, the lowest producer of IL-2 (24 U/ml), was not tumorigenic even when 107
cells were injected. Among the tumorigenic clones the latency period of tumor de-
velopment varied from 29 to 75 d (Table III).
To address the question as to whether these differences among clones in tumorige-
nicity and the latency period would be based on an unknown property specific to
mAb Dilution K21-1 T6
HT-2 stim-
ulated with
IL-41
cpm
- - 40,168 44,395 42,010
AMT-13, 1 :500 2,964 (93)lí 5,573 (87) 40,824(3)
1 :2,500 22,906 (43) 20,407 (54) 42,667 (0)
7D4 + 3C75 1 :500 7,536 (81) 10,518 (76) 37,486 (11)
1 :2,500 24,096 (40) 22,667 (49) 42,311 (0)
DMS-1 1 1 :20 8,289 (79) 21,384 (52) 39,468(6)
1 :500 26,532 (34) 31,100 (30) 42,281 (0)
11811 1 1 :20 40,873 (0) 42,088 (5) 1,211 (97)
1 :500 38,658 (4) 41,106 (7) 7,688 (82)t ~-° 14-
o g_
û
cn 4-
IV
2-
10 20 30 40 50 60 70
Latency Perlod (days)
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TABLE III
Tumorigenicity of IL-2 cDNA-transfected HT-2 cells
BALB/c (either irradiated or not) and BALB/c nu/nu mice were inoculated subcutaneously with the indi-
cated number of cells from individual cell lines (see Table I for the plasmids introduced into cell lines).
The animals were observed for aminimum period of 20 wk for the formation oftumors >1 cm in diameter.
Results are expressed as the fraction number of mice with tumor per number of mice injected.
The average of time after inoculation before tumors became visible.
each clone or would just correlate with the level of IL-2 production, 10 subclones
derived from K21-1, which differed in the level of IL-2 secretion (120-1,227 U/ml),
were tested for their tumorigenicity in nude mice (Fig. 4). Although all of the sub-
clones (107 cells per injection) produced tumors by 70 d after injection, the latency
period of tumor development showed a clear correlation with the level ofIL-2 secreted
by an individual subclone : a higher producer of IL-2 gave rise to a tumor in a shorter
period.
We next examined the growth properties in vitro of tumor cells to test the possi-
bility that a mutation(s) in vivo such as an activation of an oncogene(s) conferred
autonomous growth on cellsthrough a mechanism(s) other than IL-2 autocrine self-
stimulation . First, cells from tumors developed in nude mice were all G418 resistant,
indicating that tumors were derived from the transfectants inoculated. Second, cells
from tumors, T6 for example, retained the ability of IL-2 production and the prolifer-
ative responsiveness to IL-2 (Table I and Fig. 2 B) . Third, the proliferation in vitro
of tumor cells was a function of cell density in the absence of exogenous IL-2 (Fig.
3 C) and was blocked by antibodies to IL-2 or IL-2-R (Table II). Thus, the growth
properties in vitro oftumorcellswere indistinguishable from those of injected trans-
fectants.
FIGURE 4.
￿
Close relationship between the latency period of tumor
development and the level ofIL-2 secretion. IL-2 cDNA transfectant
K21-1 was subcloned by limiting dilution method, and 10 subclones,
which differed in the level of IL-2 secretion, were chosen for analysis
oftheir tumorigenicity. Four nude mice were inoculated subcutane-
ously with 107 cells ofeach subclone. The average oftime (days) after
inoculation before tumors become >1 cm in diameter is plotted vs.
the level of IL-2 secreted in vitro by each subclone (units/milliliter/106
cells/48 h).
Cell line
BALB/c
106 cells 107 cells
BALB/c
(300 rad irradiated)
106 cells 107 cells
BALB/c
106 cells
nu/nu
107 cells
HT-2 0/5 0/5 0/5 0/5 0/5 015
H6 0/5 0/5 0/5 0/5 0/5 0/5
H15 0/5 0/5 0/5 0/5 0/5 0/5
K9-18 0/5 0/5 0/5 015 5/5 (64 d)* 5/5 (49 d)
K21-1 0/5 0/5 0/5 015 8/8 (39 d) 10/10 (29 d)
K26-16 0/5 0/5 0/5 0/5 0/5 2/5 (75 d)
K28-6 0/5 0/5 0/5 015 0/5 01520
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Discussion
The autocrine nature of the IL-2 cDNA-transfected HT-2 cells established in this
experiment was warranted by four lines of evidence: (a) the transfectants constitu-
tively secreted biologically active IL-2 into the culture media; (b) they responded
by proliferation to added rIL-2 as well as to their own secreted IL-2; (c) their growth
was a function of the cell density; and (d) the proliferation was inhibited by mAbs
to IL-2 as well as to IL-2-R. The data are consistent with the concept of autocrine
self-stimulation but not with the growth autonomy by spontaneous mutations.
Recent work by Yamada et al . (23) has demonstrated that a murine cytotoxic T
cell line CTLL-2 infected with a retroviral expression vector carrying a human IL-2
cDNA proliferated in vitro in the absence of exogenous IL-2 and developed tumors
when injected into syngeneic or nude mice. However, the growth property of the
CTLL-2 transfectants is different from that of our HT-2 transfectants. First, the
secretion of IL-2 from the CTLL-2 transfectants was hardly detectable in the cul-
ture supernatant. One may argue that this is due to the continuous consumption
of IL-2 for their autonomous growth . However, that is not the case in our HT-2
transfectants, because the accumulation of autogenous IL-2 in the culture media
is required for the autonomous growth of the HT-2 transfectants (Fig. 3) . Indeed,
when the HT-2 transfectants were cultured at too low cell density, IL-2 activity was
undetectable in the culture supernatants, and the transfectants died. Second, the
CTLL-2 transfectants did not have responsiveness to exogenous IL-2. The addition
of IL-2 did not augment but rather suppressed their proliferation. The effect ofanti-
IL-2 antibodies to the proliferation was not examined in their study. Third, an anti-
IL-2-R mAb, AMT-13, blocked only partially the proliferation of the CTLL-2 trans-
fectants even at a higher concentration than that sufficient to inhibit completely the
IL-2-induced proliferation of untransfected CTLL-2 cells. Thus, the growth autonomy
observed in the CTLL-2 transfectants seems to be mediated through a different mech-
anism than that in the HT-2 transfectants. It is possible that in the CTLL-2 transfec-
tants the ligand may interact with the receptor mainly at some intracellular loca-
tion, being distinct from the external receptor-ligand interaction actually occurring
in our HT-2 transfectants. However, no experimental proofis available at the moment.
The establishment of T cell clones that proliferated autonomously through auto-
crine mechanism gave us the opportunity to assess the autocrine hypothesis that
states: cells could escape from the normal growth control and become malignant
by endogenous production of a growth factor(s) acting on themselves. Supporting
this hypothesis is the presence of a human T cell lymphoma line that secretes IL-2
and expresses IL-2-R (13). mAbs directed against either IL-2 or IL-2-R blocked
the proliferation of this malignant T cell line. In the present study we showed that
the T cell clones proliferating in vitro by IL-2 autocrine self-stimulation developed
tumors when injected into nude mice (Table III). The tumorigenicity apparently
correlated with the level of IL-2 secreted. A clone expressing a low level of IL-2 did
not produce any tumors, in contrast to the CTLL-2 transfectants described by Yamada
et al. (23). Among tumorigenic clones of the HT-2 transfectants, the latency period
of tumor development showed the clear relationship to the level of IL-2 secreted by
an individual clone (Fig. 4). Interestingly, none of the HT-2 transfectants, regard-
less of the level of IL-2 secretion, developed tumors in syngeneic BALB/c mice, un-
like the CTLL-2 transfectants.KARASUYAMA ET AL.
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It is unlikely that the HT-2 transfectants could become tumorigenic in vivo by
a mutation(s) that abrogated the requirement for IL-2 autocrine self-stimulation,
because cellsobtained from tumors proliferated in vitro in an IL-2 autocrine fashion
indistinguishable from that of the inoculated cells (Tables I and II, Figs. 2 B and
3 C). It has been known that bovine papillomavirus DNA present in the expression
vector BCMGNeo can transform certain epithelial and fibroblastic cell lines such
as NIH3T3, FR3T3, and C127 cells (35, 36), but not other types of cells. In fact,
none ofHT-2 cells transfected with thevector alone produced tumors in vivo (Table
III: H6, H15) . Thus, it is likely that an aberrant operation of the IL-2 autocrine
mechanismleads Tcellsto malignanttransformation. Itremains tobeclarified whether
the IL-2 autocrine self-stimulation in itself issufficient fortumorigenesis orwhether
other synergistic event(s) are required to occur concomitantly.
It has been suggested that the aberrant activation of an IL-2 autocrine loop in
CD4+ helper T cells infected with HTLU1 contributes to the pathogenesis ofATL.
ATL cells as well as T cells transformed by HTLU1, unlike normal activated Tcells,
constitutively express IL-2 receptors on their cell surfaces (15, 17, 37), suggesting
the abnormal regulation of IL-2-R expression in those cells. While HTLU1 does
not containaviraloncogene related to acellular gene(38), it possessesatrans-activator
(tat I or p40") gene whose product is able to stimulate transcription of other viral
genes from theviral longterminal repeat (39-42). Tat I hasbeen revealed to activate
the expression ofgenes encoding IL-2-R as well as IL-2 in T cells (19-22). Some
in vitro celllinesestablished fromATLpatients havebeen reported to constitutively
secrete and respond to IL-2 (16). It has also been demonstrated that leukemic cells
in the peripheral blood of a patient with ATL responded to IL-2 secreted by them-
selves and their proliferation was inhibited by anti-IL-2 or anti-IL-2-R mAbs (18).
The resemblance with the growth property ofthese ATL cells and our HT-2 trans-
fectants is striking. It is likely from our results that a higher producer of IL-2 has
a growth advantage and thereby becomes a predominant clone among HTLU1-
infected T cells that proliferate polyclonally by IL-2 autocrine self stimulation.
In most cases of ATL, with some exceptions (43-44), leukemic T cells respond
poorly to IL-2 in vitro (45) and rarely produce IL-2 (46), which suggests an addi-
tional abnormality(ies) rendering infected T cells to go from IL-2 dependent to IL-2
independent. We obtainedseveralvariant clones from mIL-2 cDNA-transfected HT-2
cells afteralong-term in vitro culture (unpublished experiments). While these vari-
ants retained the ability to secrete IL-2, they did not respond to exogenous IL-2
and their proliferation was not inhibited anymore by antibodies to IL-2 or IL-2-R.
Such a transition from a factor-dependent to -independent state has been also ob-
served in GM-CSFdependent cell lines infected with a retrovirus vector carrying
GM-CSF cDNA, though their tumorigenicity has not been tested (47). These ob-
servationsmay indicatewhat wouldhappen in HTLU1-infected T cells. Our propo-
sition in this paper is that the IL-2 autocrine self-stimulation is involved in at least
some stage(s) ofthe transforming process of HTLU1-infected T cells. In efforts to
further elucidate the role ofIL-2 autocrine mechanism in the development ofATL
and other T cell malignancies, it will be ofinterest to determine how an additional
genetic alteration(s) correlates with IL-2 autocrine self-stimulation in the variant
clones of HT-2 transfectants.22
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Summary
We introduced a mouse IL-2 cDNA expression vector into an IL-2-dependent
mouse helper T cell line HT2 . Transfected cells secreted substantial amounts of
IL-2, to which they themselves responded by proliferating without further require-
ment for exogenous IL-2. The proliferation was a direct function of the cell density
and was inhibitable by antibodies against IL-2 or IL-2-R, indicating the autocrine
nature of the proliferation. Those producing higher amounts of IL-2 were found
to be tumorigenic when inoculated into nude mice. The latency period of tumor
development correlated inversely with the level of IL-2 secreted. Tumor cellsprolifer-
ated in vitro in an IL-2 autocrine fashion indistinguishable from that of the inocu-
lated cells. We thus provide evidence that the aberrant activation of the IL-2 auto-
crine circuit can lead T cells to malignant transformation.
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